Daniel Fierer is an Infectious Disease physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 66 publications with 4,391 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingMedicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
36.9%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor14.4%Descovy54%Triumeq41%Abacavir-Lamivudine4%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor11.6%Tivicay73%Isentress15%Dovato7%Isentress Hd5%Part D<11 patients+ 7 more classes in this area
Cardiovascular
26.4%Statin11.4%Atorvastatin Calcium81%Pravastatin Sodium14%Rosuvastatin Calcium6%Part D<11 patientsBeta blocker4.5%Carvedilol33%Metoprolol Tartrate26%Atenolol16%Labetalol Hcl13%Metoprolol Succinate12%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
13.6%GLP-1 receptor agonist4.6%Ozempic59%Mounjaro28%Trulicity13%Part D<11 patientsBiguanide (metformin)3.6%Metformin Hcl79%Metformin Hcl Er21%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2002–2006 per NIH RePORTER. The latest:
- Persistent Reservoirs of HIV-1 Infection
Icahn School of Medicine at Mount Sinai
FY2006$148,144K23AI050449 - MVA SMALLPOX VACCINE IN ADULTS WITH AND WITHOUT PREVIOUS SMALLPOX VACCINE
Icahn School of Medicine at Mount Sinai
FY2006$3,753M01RR000071 - Persistent Reservoirs of HIV-1 Infection
Mount Sinai School of Medicine of Nyu
FY2005$148,144K23AI050449
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”